Inhibrx Biosciences (NASDAQ:INBX) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?

Posted by Francis Steltz on Oct 28th, 2026

Inhibrx Biosciences, Inc. (NASDAQ:INBX – Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $91.47 and traded as low as $86.92. Inhibrx Biosciences shares last traded at $88.61, with a volume of 251,182 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on INBX. Citigroup reaffirmed a “market perform” rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th. HC Wainwright initiated coverage on Inhibrx Biosciences in a research report on Monday, August 24th. They set a “buy” rating and a $245.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Friday, September 11th. Finally, Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $197.50.

Get Our Latest Report on Inhibrx Biosciences

Inhibrx Biosciences Stock Down 23.4%

The stock’s 50-day moving average is $103.45 and its 200 day moving average is $91.62. The stock has a market capitalization of $1.08 billion, a PE ratio of -8.25 and a beta of 3.81.

Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing the consensus estimate of ($2.28) by ($0.06). As a group, equities research analysts forecast that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current year.

Insider Activity at Inhibrx Biosciences

In related news, Director Kimberly Manhard sold 500 shares of Inhibrx Biosciences stock in a transaction on Monday, September 14th. The stock was sold at an average price of $110.26, for a total transaction of $55,130.00. Following the completion of the sale, the director owned 8,000 shares of the company’s stock, valued at approximately $882,080. This trade represents a 5.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Douglas Forsyth acquired 2,500 shares of Inhibrx Biosciences stock in a transaction that occurred on Tuesday, September 8th. The shares were purchased at an average cost of $114.65 per share, with a total value of $286,625.00. Following the transaction, the director owned 227,064 shares of the company’s stock, valued at approximately $26,032,887.60. The trade was a 1.11% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have acquired 62,540 shares of company stock valued at $6,347,507 and have sold 1,500 shares valued at $168,590. Corporate insiders own 18.26% of the company’s stock.

Institutional Investors Weigh In On Inhibrx Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Opaleye Management Inc. acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth $1,923,000. Nicholas Investment Partners LP bought a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at $2,032,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Inhibrx Biosciences by 29,850.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 20,067 shares of the company’s stock valued at $1,901,000 after purchasing an additional 20,000 shares in the last quarter. Western Standard LLC bought a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at $4,453,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Inhibrx Biosciences in the 2nd quarter valued at $2,482,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc is a biotechnology company focused on developing biologic medicines for serious and rare diseases. The company uses its proprietary protein-engineering and antibody-development platforms to create therapies designed to address conditions with limited treatment options.

Its lead investigational program was INBRX-101, an engineered recombinant protein developed for alpha-1 antitrypsin deficiency-associated lung disease. The company also advanced other potential treatments, including INBRX-109, an investigational therapy studied in certain solid tumors, and additional biologic candidates targeting oncology and other serious diseases.